Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Inhibitory effects of kukoamine B on adipogenesis and lipid accumulation in vitro and obesity in vivo.

Oh KI., Lee SJ., Kim J., Jeong J., Bae MH., Park E.

Animal Study on Type 2 Diabetes, published in Biomed Pharmacother (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomed Pharmacother (2025)
Country
France
Reported sample size
—
Source database
PubMed
PMID
40347845
DOI
10.1016/j.biopha.2025.118143

Abstract (original English)

Obesity, characterized by excessive adipose tissue accumulation, is an important risk factor for the development of several chronic conditions, including cardiovascular disease, type 2 diabetes mellitus, and hypertension. The present study aimed to investigate the effects of kukoamine B (KB), a major component of the Lycii Radicis Cortex (LRC), on adipogenesis and lipid accumulation in vitro and further assess its role in obesity in vivo. For the in vitro experiments, 3T3-L1 cells and primary-cultured adipose-derived stem cells were used. Lipid accumulation was measured using Oil Red O staining, and adipogenesis-related gene expression was assessed using quantitative reverse transcription polymerase chain reaction. For the in vivo experiments, LRC or KB was orally administered to ovariectomized and high-fat diet-induced obese mice. LRC exhibited antiadipogenic and antiobesity effects in vitro and in vivo experiments. Fractionation of the LRC extract identified KB as a bio-active component. KB treatment resulted in a dose-dependent reduction in lipid droplet formation and downregulation of adipogenesis-related genes, including Pparg, Cebpa, Srebp1, Fasn, and Plin2, in both cell types. Western blot analysis revealed that KB significantly suppressed the protein expression of key adipogenic factors, including phosphorylated CREB, CEBPB, PPARG, and CEBPA. In vivo, KB administration

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsAdipogenesis3T3-L1 CellsObesityMiceLipid MetabolismFemaleMice, Inbred C57BLDiet, High-FatAdipocytes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research